ARTICLE | Strategy
Teva's balancing act
Analysis of Teva's growth strategy after acquiring Cephalon
May 9, 2011 7:00 AM UTC
Acquiring Cephalon Inc. gives Teva Pharmaceutical Industries Ltd.'s branded drug business a significant boost, but the Israeli pharma will need more acquisitions to achieve its growth goals.
In January 2010, Teva laid out a strategy to more than double its sales to $31 billion in 2015 from $13.9 billion in 2009. The company intends to accomplish this via organic growth and acquisitions...